Phaseline

Targets › ACE2

ACE2 (Angiotensin-converting enzyme 2): drug programs, companies and trials

4 programs from 3 companies in 4 trials: 2 Phase 3, 2 Phase 1; Oncology, Neurology, Cardiovascular; next expected readout Dec 2026.

Essential counter-regulatory carboxypeptidase of the renin-angiotensin hormone system that is a critical regulator of blood volume, systemic vascular resistance, and thus cardiovascular homeostasis. Converts angiotensin I to angiotensin 1-9, a nine-amino acid peptide with anti-hypertrophic effects in cardiomyocytes, and angiotensin II to angiotensin 1-7, which then acts as a beneficial vasodilator and…. (UniProt, Q9BYF1)

Open in Phaseline: the race on ACE2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Monash UniversityElasomeran
Spike glycoprotein vaccine antigen
ACE2Phase 3HIVDec 2026
Monash UniversityPfizer Bivalent COVID-19 Vaccine
mRNA vaccine encoding SARS-CoV-2 spike protein (original strain and Omicron BA.1)
ACE2Phase 3HIVDec 2026
University of ArizonaAngiotensin (1-7)
Angiotensin (1-7) receptor agonist; acts through the Mas receptor to promote neuroprotecti
ACE2Phase 1Traumatic Brain InjurySep 2027
Vanderbilt UniversityAngiotensin-(1-7)
Angiotensin-(1-7) receptor agonist; endogenous peptide that promotes vasodilation and may
ACE2Phase 1ObesityDec 2029

Conditions

HIV (2) Traumatic Brain Injury (1) Obesity (1)

Modalities

other (2), small molecule (2)

Companies

Monash University (2) University of Arizona (1) Vanderbilt University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.